Topic Hub
24 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 24 of 24 clinical reviews.
A physician-level review of lemborexant (Dayvigo) pharmacokinetics, dosing, and safety after bariatric surgery, with primary-literature citations and clinical decision frameworks.
Read clinical reviewDoes lemborexant (Dayvigo) affect appetite or cravings? A clinical review of orexin biology, SUNRISE trial data, and real-world patterns in patients taking this dual orexin receptor antagonist for insomnia.
Read clinical reviewA clinical deep-dive into lemborexant (Dayvigo) use in autoimmune disease, covering orexin system immunology, drug interactions with DMARDs and biologics, sleep architecture effects, and dosing guidance for patients with rheumatoid arthritis, lupus, MS, and IBD.
Read clinical reviewA clinical review of lemborexant (Dayvigo) and its effects on bone health and density, including orexin biology, comparative data from benzodiazepine and Z-drug studies, fall-fracture risk, and practical guidance for prescribers managing older patients with insomnia.
Read clinical reviewA physician-level review of lemborexant (Dayvigo) and cancer risk signals. Covers FDA labeling, postmarket surveillance, orexin biology, clinical trial data, and how to counsel patients asking about the Dayvigo cancer risk signal.
Read clinical reviewA clinician-level review of lemborexant (Dayvigo) cardiovascular safety data, including blood pressure, heart rate, QTc, and long-term outcomes from SUNRISE-1, SUNRISE-2, and post-market surveillance.
Read clinical reviewA physician-reviewed deep dive into how lemborexant (Dayvigo) affects next-morning cognition, driving performance, and memory, with primary-literature citations from SUNRISE-1 and beyond.
Read clinical reviewA physician-level comparison of compounded lemborexant vs. Branded Dayvigo covering pharmacology, clinical trial evidence, regulatory status, dosing, cost, and safety for patients and prescribers.
Read clinical reviewA GRADE-level analysis of lemborexant (Dayvigo) clinical evidence, covering SUNRISE-1, SUNRISE-2, head-to-head comparators, safety data, and what each finding means for prescribing decisions.
Read clinical reviewDoes lemborexant (Dayvigo) cause hair loss or skin changes? A clinician-reviewed deep dive into the pharmacology, clinical trial data, and post-marketing reports to help you weigh the real risks.
Read clinical reviewA physician-reviewed deep dive into how lemborexant (Dayvigo) affects liver function, hepatic metabolism, and ALT/AST levels, with primary-literature citations and dosing guidance for patients with hepatic impairment.
Read clinical reviewA clinician-level review of lemborexant (Dayvigo) and its effects on mood, anxiety, depression, and next-day cognitive function, drawing on SUNRISE-1, FDA labeling, and current sleep-psychiatry literature.
Read clinical reviewA physician-level review of lemborexant (Dayvigo) metabolism, CYP3A4 pharmacokinetics, and effects on energy expenditure, thermogenesis, and orexin-pathway physiology.
Read clinical reviewA physician-reviewed deep dive into lemborexant (Dayvigo) microdosing protocols, covering FDA-approved dosing, the SUNRISE trial data, off-label sub-threshold use, pharmacokinetics, and what clinicians need to know before adjusting doses below 5 mg.
Read clinical reviewA physician-reviewed guide to lemborexant (Dayvigo) muscle preservation strategies, covering orexin biology, sleep architecture effects on protein synthesis, and practical protocols for patients at risk of sarcopenia.
Read clinical reviewMD/PharmD-level guide to diagnosing and managing lemborexant (Dayvigo) plateau and non-response: dose optimization, comorbidity review, combination strategies, and when to switch agents.
Read clinical reviewA physician-level guide to the lemborexant (Dayvigo) pre-surgery hold window: pharmacokinetics, anesthesia interactions, CNS depression risk, and step-by-step perioperative management protocols.
Read clinical reviewA physician-reviewed, evidence-based guide to lemborexant (Dayvigo) rebound insomnia and discontinuation effects, covering mechanism, SUNRISE trial data, tapering strategies, and when to seek clinical support.
Read clinical reviewA physician-reviewed deep dive into lemborexant (Dayvigo) and kidney safety. Covers pharmacokinetics, CKD dosing, clinical trial data, and practical guidance for patients with renal impairment.
Read clinical reviewLearn exactly how and when to restart lemborexant (Dayvigo) after acute illness, with dose-adjustment guidance, drug-interaction checks, and primary-literature citations reviewed by the HealthRX medical team.
Read clinical reviewA clinical deep-dive into lemborexant (Dayvigo) seasonal use considerations, covering circadian light shifts, DST transitions, SAD overlap, dose timing, and drug interactions across all four seasons.
Read clinical reviewA clinician-level review of lemborexant (Dayvigo) and sexual function, covering orexin biology, SUNRISE trial data, comparisons with other sleep drugs, and practical prescribing guidance.
Read clinical reviewA clinician-level review of how lemborexant (Dayvigo) reshapes sleep architecture, from REM and slow-wave changes to next-morning function, with primary-trial citations throughout.
Read clinical reviewBoard-reviewed clinical protocols for using lemborexant (Dayvigo) during travel and timezone shifts. Covers dosing timing, jet lag physiology, SUNRISE-1 data, and next-morning alertness considerations.
Read clinical review